Suven Life Sciences Ltd.
SUVEN · ISIN: INE495B01038
Suven Life Sciences Ltd. is a small cap company in the Healthcare Services sector, listed on the NSE under ISIN INE495B01038.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
CHART
Suven Life Sciences Ltd. - growth of ₹100
Growth of ₹100 invested on 2026-09-30, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-17.49%
3M
-13.97%
6M
+24.69%
1Y
+32.32%
3Y CAGR
+47.91%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Suven Life Sciences Ltd. - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-06-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-06-30.
Corporate Actions
| Ex-Date | Type | Ratio | Details |
|---|---|---|---|
| 2022-10-17 | RIGHTS | 1.000000 | RIGHTS 1:2 @ PREMIUM RS 54/- |
| 2020-01-21 | SPLIT | 0.052911 | implied_from_price |
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-08-17 | SHORT_SELL | 190 |
Frequently asked questions
What is Suven Life Sciences Ltd.'s 1-year and 3-year return?
Suven Life Sciences Ltd.'s 1-year price return is +32.32%. Its 3-year CAGR (annualized return) is +47.91%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Suven Life Sciences Ltd.'s latest financial performance?
Suven Life Sciences Ltd.'s trailing-twelve-month (TTM) revenue as of 2026-06-30 is ₹9 Cr, with a TTM profit after tax of ₹-352 Cr and an EBITDA margin of -3991.51%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹-14.89.
What is Suven Life Sciences Ltd.'s quality score?
Suven Life Sciences Ltd. has a Punji quality score of 37.5 out of 100 as of 2026-06-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do Suven Life Sciences Ltd.'s technical indicators show?
As of 2026-10-29, Suven Life Sciences Ltd.'s RSI (14-day) is 31.83 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of Suven Life Sciences Ltd.?
As of 2026-06-30, Suven Life Sciences Ltd.'s shareholding is split across Promoter (65.47%), Public (34.53%), NonPromoterNonPublic (null%). Promoter holding of 65.47% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Has Suven Life Sciences Ltd. seen any recent bulk or block deals?
Yes, as of 2026-08-17 - the most recent recorded deal was a SHORT_SELL on 2026-08-17 for 190 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
What corporate actions has Suven Life Sciences Ltd. announced recently?
The most recent corporate action for Suven Life Sciences Ltd. is a RIGHTS (1.000000) with an ex-date of 2022-10-17, for: RIGHTS 1:2 @ PREMIUM RS 54/-. The ex-date is the cutoff - only shareholders who held the stock before this date qualify for the action (dividend, split, bonus, or rights issue, depending on type). Corporate actions typically adjust the stock's price and/or share count mechanically on the ex-date, which is why historical price charts are usually shown adjusted for these events.
Stock data · Not financial advice · Past performance does not indicate future returns